Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) shares were up 0.5% on Thursday . The stock traded as high as $4.42 and last traded at $4.39. 435,521 shares were traded during mid-day trading, an increase of 67% from the average session volume of 261,100 shares. The stock had previously closed at $4.37.
Aadi Bioscience Trading Up 0.5%
The company’s 50 day moving average price is $4.25 and its two-hundred day moving average price is $3.45. The firm has a market cap of $108.42 million, a PE ratio of -1.93 and a beta of 0.68.
About Aadi Bioscience
Aadi Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI. The company’s research strategy centers on identifying molecular drivers of tumor growth and designing small-molecule inhibitors that target these pathways.
The company’s lead product candidate, fimepinostat (CUDC-907), is a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K).
Featured Articles
- Five stocks we like better than Aadi Bioscience
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
